{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T11:52:27Z","timestamp":1791114747303,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-026-05428-2","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:04:58Z","timestamp":1790964298000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predicting clinically significant prostate cancer in PI-RADS 3 lesions: an internally validated PSA density-based model with decision-curve analysis"],"prefix":"10.1007","author":[{"given":"Federico","family":"Rovegno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Pillai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniket","family":"Deshpande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Corr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"key":"5428_CR1","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/bju.14017","volume":"121","author":"A Borkowetz","year":"2018","unstructured":"Borkowetz A, Hadaschik B, Platzek I, Toma M, Torsev G, Renner T et al (2018) Prospective comparison of transperineal magnetic resonance imaging\/ultrasonography fusion biopsy and transrectal systematic biopsy in biopsy-na\u00efve patients. BJU Int 121:53\u201360","journal-title":"BJU Int"},{"key":"5428_CR2","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/bju.14049","volume":"122","author":"NL Hansen","year":"2018","unstructured":"Hansen NL, Barrett T, Kesch C, Pepdjonovic L, Bonekamp D, O\u2019Sullivan R et al (2018) Multicentre evaluation of magnetic resonance imaging supported transperineal prostate biopsy in biopsy-na\u00efve men with suspicion of prostate cancer. BJU Int 122:40\u201349","journal-title":"BJU Int"},{"key":"5428_CR3","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","volume":"378","author":"V Kasivisvanathan","year":"2018","unstructured":"Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH et al (2018) MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med 378:1767\u20131777","journal-title":"N Engl J Med"},{"key":"5428_CR4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.eururo.2014.03.002","volume":"66","author":"MR Pokorny","year":"2014","unstructured":"Pokorny MR, de Rooij M, Duncan E, Schr\u00f6der FH, Parkinson R, Barentsz JO et al (2014) Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies. Eur Urol 66:22\u201329","journal-title":"Eur Urol"},{"key":"5428_CR5","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.euf.2019.06.014","volume":"6","author":"M Maggi","year":"2020","unstructured":"Maggi M, Panebianco V, Mosca A et al (2020) Prostate imaging reporting and data system 3 category cases at multiparametric magnetic resonance for prostate cancer: a systematic review and meta-analysis. Eur Urol Focus 6:463\u2013478","journal-title":"Eur Urol Focus"},{"issue":"4","key":"5428_CR6","first-page":"115","volume":"15","author":"CS Lim","year":"2021","unstructured":"Lim CS, Abreu-Gomez J, Leblond M-A et al (2021) When to biopsy Prostate Imaging and Data Reporting System version 2 (PI-RADSv2) assessment category 3 lesions? Use of clinical and imaging variables to predict cancer diagnosis at targeted biopsy. Can Urol Assoc J 15(4):115\u2013121","journal-title":"Can Urol Assoc J"},{"issue":"1","key":"5428_CR7","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1148\/radiol.2016161124","volume":"283","author":"AB Rosenkrantz","year":"2017","unstructured":"Rosenkrantz AB, Babb JS, Taneja SS, Ream JM (2017) Proposed adjustments to PI-RADS version 2 decision rules: impact on prostate cancer detection. Radiology 283(1):119\u2013129","journal-title":"Radiology"},{"key":"5428_CR8","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.euf.2018.02.012","volume":"5","author":"J Gomez Rivas","year":"2019","unstructured":"Gomez Rivas J, Giganti F, Alvarez-Maestro M et al (2019) Prostate indeterminate lesions on magnetic resonance imaging-biopsy vs. surveillance: A literature review. Eur Urol Focus 5:799\u2013806","journal-title":"Eur Urol Focus"},{"key":"5428_CR9","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1148\/radiol.2019182946","volume":"292","author":"AR Padhani","year":"2019","unstructured":"Padhani AR, Barentsz J, Villeirs G et al (2019) PI-RADS Steering Committee: the PI-RADS multiparametric MRI and MRI-directed biopsy pathway. Radiology 292:464\u2013474","journal-title":"Radiology"},{"key":"5428_CR10","doi-asserted-by":"publisher","DOI":"10.1177\/20514158241267083","author":"U Walters","year":"2024","unstructured":"Walters U, Winkler M, Heer R et al (2024) A clinician survey on the current practices within the prostate cancer diagnostic pathway in the United Kingdom. J Clin Urol. https:\/\/doi.org\/10.1177\/20514158241267083","journal-title":"J Clin Urol"},{"key":"5428_CR11","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/bju.13465","volume":"119","author":"S Washino","year":"2017","unstructured":"Washino S, Okochi T, Saito K et al (2017) Combination of Prostate Imaging Reporting and Data System (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy-naive patients. BJU Int 119:225\u2013233","journal-title":"BJU Int"},{"key":"5428_CR12","doi-asserted-by":"publisher","first-page":"132","DOI":"10.21037\/tau.2017.12.29","volume":"7","author":"IG Schoots","year":"2018","unstructured":"Schoots IG, Osses DF, Drost FH et al (2018) Reduction of MRI-targeted biopsies in men with low-risk prostate cancer on active surveillance by stratifying to PI-RADS and PSA-density, with different thresholds for significant disease. Transl Androl Urol 7:132\u2013144","journal-title":"Transl Androl Urol"},{"key":"5428_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g7594","volume":"350","author":"GS Collins","year":"2015","unstructured":"Collins GS, Reitsma JB, Altman DG, Moons KGM (2015) Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ 350:g7594","journal-title":"BMJ"},{"issue":"3","key":"5428_CR14","doi-asserted-by":"publisher","first-page":"499","DOI":"10.21037\/tau.2017.05.31","volume":"6","author":"M Scialpi","year":"2017","unstructured":"Scialpi M, Rondoni V, Aisa MC, Martorana E, D\u2019Andrea A, Malaspina CM et al (2017) Is contrast enhancement needed for diagnostic prostate MRI? Transl Androl Urol 6(3):499\u2013509","journal-title":"Transl Androl Urol"},{"issue":"7","key":"5428_CR15","doi-asserted-by":"publisher","first-page":"4039","DOI":"10.1007\/s00330-020-06782-0","volume":"30","author":"JP Zawaideh","year":"2020","unstructured":"Zawaideh JP, Sala E, Shaida N, Koo B, Warren AY, Carmisciano L et al (2020) Diagnostic accuracy of biparametric versus multiparametric prostate MRI: assessment of contrast benefit in clinical practice. Eur Radiol 30(7):4039\u20134049","journal-title":"Eur Radiol"},{"issue":"4","key":"5428_CR16","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s00345-018-2428-y","volume":"37","author":"D Junker","year":"2019","unstructured":"Junker D, Steinkohl F, Fritz V, Bektic J, Tokas T, Aigner F et al (2019) Comparison of multiparametric and biparametric MRI of the prostate: are gadolinium-based contrast agents needed for routine examinations? World J Urol 37(4):691\u2013699","journal-title":"World J Urol"},{"issue":"5","key":"5428_CR17","doi-asserted-by":"publisher","first-page":"410","DOI":"10.37554\/en-j.arch.esp.urol-20210717-3506-26","volume":"75","author":"MY Koparal","year":"2022","unstructured":"Koparal MY, S\u00f6zen TS, Kar\u015fiyakali N, Akdo\u011fan B, \u00d6zen H, Aslan G, T\u00fcrkeri L (2022) Should targeted biopsy be performed in patients who have only PI-RADS 3 lesions? Arch Esp Urol 75(5):410\u2013415","journal-title":"Arch Esp Urol"},{"key":"5428_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.03.039","author":"JP Radtke","year":"2017","unstructured":"Radtke JP, Wiesenfarth M, Kesch C et al (2017) Combined clinical parameters and multiparametric magnetic resonance imaging for advanced risk modeling of prostate cancer: patient-tailored risk stratification can reduce unnecessary biopsies. Eur Urol. https:\/\/doi.org\/10.1016\/j.eururo.2017.03.039","journal-title":"Eur Urol"},{"issue":"7","key":"5428_CR19","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.acuro.2024.01.003","volume":"48","author":"A Ayranci","year":"2024","unstructured":"Ayranci A, Caglar U, Meric A, Gelmis M, Sarilar O, Ozgor F (2024) Effects of the lesion size on clinically significant prostate cancer detection rates in PI-RADS category 3\u20135 lesions. Actas Urol Esp (Engl Ed) 48(7):526\u2013531","journal-title":"Actas Urol Esp (Engl Ed)"},{"issue":"2","key":"5428_CR20","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.euf.2019.11.012","volume":"7","author":"M G\u00f6rtz","year":"2021","unstructured":"G\u00f6rtz M, Radtke JP, Hatiboglu G et al (2021) The value of prostate-specific antigen density for prostate imaging-reporting and data system 3 lesions on multiparametric magnetic resonance imaging: a strategy to avoid unnecessary prostate biopsies. Eur Urol Focus 7(2):325\u2013331","journal-title":"Eur Urol Focus"},{"issue":"3","key":"5428_CR21","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.euo.2018.09.001","volume":"2","author":"L Boesen","year":"2019","unstructured":"Boesen L, N\u00f8rgaard N, L\u00f8gager V, Balslev I, Bisbjerg R, Thestrup KC, Jakobsen H, Thomsen HS (2019) Prebiopsy biparametric magnetic resonance imaging combined with prostate-specific antigen density in detecting and ruling out Gleason 7-10 prostate cancer in biopsy-na\u00efve men. Eur Urol Oncol 2(3):311\u2013319","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"5428_CR22","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.euo.2023.08.002","volume":"7","author":"S Wang","year":"2024","unstructured":"Wang S, Kozarek J, Russell R, Drescher M, Khan A, Kundra V, Barry KH, Naslund M, Siddiqui MM (2024) Diagnostic performance of prostate-specific antigen density for detecting clinically significant prostate cancer in the era of magnetic resonance imaging: a systematic review and meta-analysis. Eur Urol Oncol 7(2):189\u2013203","journal-title":"Eur Urol Oncol"},{"key":"5428_CR23","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford P, van den Bergh RCN, Briers E et al (2024) EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer\u20142024 update. Part I: screening, diagnosis, and local treatment with curative intent. Eur Urol 86:148\u2013163","journal-title":"Eur Urol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05428-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-026-05428-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05428-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T11:01:49Z","timestamp":1791111709000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-026-05428-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":23,"alternative-id":["5428"],"URL":"https:\/\/doi.org\/10.1007\/s11255-026-05428-2","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]},"assertion":[{"value":"11 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest related to this work.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}